Pharmacokinetics of Artesunate in Pregnant Women with Malaria
Author Information
Author(s): Onyamboko Marie A, Meshnick Steven R, Fleckenstein Lawrence, Koch Matthew A, Atibu Joseph, Lokomba Victor, Douoguih Macaya, Hemingway-Foday Jennifer, Wesche David, Ryder Robert W, Bose Carl, Wright Linda L, Tshefu Antoinette K, Capparelli Edmund V
Primary Institution: Kinshasa School of Public Health, Kinshasa, The Democratic Republic of Congo
Hypothesis
The study investigates the pharmacokinetics and safety of artesunate in pregnant women with asymptomatic Plasmodium falciparum infections.
Conclusion
A single dose of orally administered artesunate was found to be effective and without adverse effects in pregnant women.
Supporting Evidence
- All pregnant women delivered live babies.
- The median birth weight was 3025 grams.
- Rates of parasite clearance by 12 hours post-dose were high and comparable among the groups.
- Rapid elimination of artesunate was observed in all three groups.
- The study suggests that additional studies on the pharmacokinetics of artesunate in pregnant women are needed.
Takeaway
Pregnant women can safely take artesunate for malaria, and it works well, but it doesn't stay in their bodies as long as it does for non-pregnant women.
Methodology
The study involved pregnant women with asymptomatic malaria and non-pregnant controls, who received a single oral dose of 200 mg artesunate, with pharmacokinetic analysis performed on plasma samples.
Potential Biases
Potential selection bias due to the specific population studied.
Limitations
The study had a small sample size and was limited to a specific geographic area.
Participant Demographics
Pregnant women aged 18-40 with asymptomatic malaria, and non-pregnant controls.
Statistical Information
P-Value
p=0.0018
Confidence Interval
90% CI [0.57, 0.81]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website